Clinical Trial

Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance

Study acronym: REaCT-TEMPO
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance. Participants will be randomized to standard daily dosing of endocrine therapy or endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-02-22; most recent amendment 2026-07-15.
Status change: Recruiting → Active, Not Recruiting 2024-08-08
Status change: Not Yet Recruiting → Recruiting 2023-08-03
Trial Details
NCT Number NCT05754528
Lead Sponsor Ottawa Hospital Research Institute
Conditions Breast Cancer
Enrollment 240 participants
Start Date 2023-07-28
Primary Completion 2025-11-25 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-16